China is rapidly emerging as a leader in pharmaceutical innovation, driven by a significant investment in artificial intelligence, which has led to record-breaking drug deals worth $110 billion in the first half of 2026.
The country is shifting from a fast follower to a pioneer in drug discovery, with AI technologies becoming essential for developing next-generation therapies. Currently, China contributes approximately 30% of new drugs in development worldwide, trailing only the United States. The surge in deal activity, with 81 transactions completed by June, reflects a growing interest from global pharmaceutical companies, particularly from the US and Europe, in collaborating with Chinese firms across various therapeutic areas including oncology and neurology.
AI is fundamentally transforming the drug development process by enabling companies to design molecules, simulate patient responses, and optimize early-stage testing more efficiently. This technological advancement allows for quicker, more accurate drug development, which can significantly reduce costs and timelines compared to traditional methods.
The integration of AI in biomedicine is enhancing China's position within the global healthcare landscape. By leveraging large datasets and advanced AI capabilities alongside a developing regulatory framework, China is establishing a robust foundation for innovation. As this momentum builds, experts speculate that China may not only keep pace with global medical advancements but could also reshape them in the years to come.